<DOC>
	<DOCNO>NCT00474435</DOCNO>
	<brief_summary>In pilot study pharmacokinetics safety antiretroviral combination co-formulated emtricitabine/tenofovir/efavirenz study HIV-positive patient pulmonary tuberculosis ( TB ) concomitantly treat standard rifampin-containing tuberculostatic regimen . It expect antiretroviral combination cause minimal drug interaction rifampin-containing anti-tuberculosis medication .</brief_summary>
	<brief_title>Pharmacokinetics Emtricitabine/Tenofovir/Efavirenz HIV-infected Patients With Tuberculosis</brief_title>
	<detailed_description>The primary objective pilot study 30 patient : 1 . To determine effect rifampin-containing tuberculostatic treatment pharmacokinetic profile emtricitabine+tenofovir+efavirenz , co-formulated one tablet , HIV-infected patient smear-positive pulmonary tuberculosis Tanzania . 2 . To determine effect emtricitabine+tenofovir+efavirenz regimen pharmacokinetics tuberculostatics population . The secondary objective : 1 . To determine safety co-administration emtricitabine+tenofovir+efavirenz treatment smear-positive pulmonary tuberculosis . 2 . To determine short-term ( 24 week ) virological efficacy HIV emtricitabine+tenofovir+efavirenz regimen patient smear-positive pulmonary tuberculosis . 3 . To determine short-term bacteriological efficacy smear-positive tuberculosis co-administration standard regimen tuberculosis emtricitabine+tenofovir+efavirenz regimen .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>A smearpositive pulmonary tuberculosis , base positive smear least two sputum sample ZiehlNeelsen ( ZN ) stain . HIVinfected document positive HIV antibody test . Subject least 18 year age day first dose study medication . Subject able willing sign Informed Consent Form prior screen evaluation . CD4 cell count &gt; 50 copies/mm3 . Karnofsky score &gt; 40 . Willing able regularly attend Kibung'oto National Tuberculosis Hospital ( KNTH ) clinic . History sensitivity/idiosyncrasy drug chemically related compound excipients , may employ trial . Previously treat HIV infection antiretroviral agent . Pregnant breastfeeding . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . A history severe psychiatric disease psychosis , schizophrenia , etc . Inability understand nature extent trial procedure require . Abnormal serum transaminase creatinine , determined level &gt; 5 time upper limit normal . Active hepatobiliary hepatic disease ( Non B Chronic Hepatitis B/C coinfection allow ) . CD4 cell count &gt; 350 cells/mm3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>HIV</keyword>
	<keyword>Coinfection</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Emtricitabine</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Rifampin</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>